Key result
Low-dose atorvastatin plus losartan matches cardioprotection of up to 100-fold higher monotherapy doses.
Why the study?
The cardiovascular pleiotropic effects of low-dose statins and ARBs separately are ineffective, but their combined effects on vascular relaxation and ischaemic-reperfusion injury are unclear.
Does the combination of low-dose atorvastatin and losartan improve aortic ring relaxation and diminish ischaemic-reperfusion injury in isolated rat hearts?
Does the combination of low-dose atorvastatin and losartan improve aortic ring relaxation and diminish ischaemic-reperfusion injury in isolated rat hearts?
Answers are grounded in this paper and cite their sources.
The combination of low-dose atorvastatin and losartan demonstrates synergistic cardiovascular protective effects in a preclinical model, suggesting a potential novel approach for cardiovascular prevention.
BACKGROUND: The cardiovascular pleiotropic effects of statins and angiotensin receptor blockers (ARBs) could be of interest for innovative preventive approaches. We aimed to investigate whether low-dose atorvastatin and losartan, separately not possessing protective cardiovascular pleiotropic effects, express them when combined. MATERIAL/METHODS: Forty-five adult male Wistar rats were anaesthetized and their thoracic aortas and hearts were isolated. Relaxation of aortic rings, coronary flow rate and the extent of myocardial ischaemic-reperfusion injury were measured. Different concentrations (0.01, 0.1, 1.0 µM) of atorvastatin and losartan added to a perfusion medium were first tested. The separate drugs, which were ineffective, were then combined at the same concentrations and the concentration was tested in the same model. RESULTS: Low concentrations of atorvastatin or losartan (0.1 and 1 µM, respectively) produced no effects in isolated aorta. However, surprisingly, when these drug concentrations were combined, a significantly improved endothelium-dependent relaxation of the thoracic aorta was observed. Similarly, when combining individually ineffective concentrations of atorvastatin or losartan (0.01 and 0.1 µM, respectively), significantly increased coronary flow and a decreased extent of myocardial injury were observed. By using a nitric oxide-synthase inhibitor, we demonstrated that the vasodilatory effects obtained were nitric oxide-dependent. The degree of effectiveness by the combination was comparable to that obtained by 10-fold (atorvastatin) or 100-fold (losartan) higher concentrations of the separate drugs. CONCLUSIONS: Our results revealed that remarkable additive/synergistic effects exist between low-doses of a statin (atorvastatin) and an ARB (losartan), resulting in important cardiovascular protection. This new concept could be valuable in cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Lunder et al. (2012) studied this question. Atorvastatin and losartan combination vs. Atorvastatin or losartan alone was evaluated on Relaxation of aortic rings, coronary flow rate, and extent of myocardial ischaemic-reperfusion injury. Combining low-dose atorvastatin and losartan achieved cardiovascular protection comparable to 10-fold and 100-fold higher concentrations of the separate drugs in isolated rat hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: